艾美捷科技特约代理EdgeBio公司产品。

EdgeBio公司拥有一批经验丰富的专业研究人员，专注于研发下一代测序技术及应用。

EdgeBio has a team of experienced research professionals that are knowledgeable in next generation sequencing technologies and applications. From library preparation through data analysis, EdgeBio representatives are there to discuss your project on a custom basis to ensure that you receive the results you need for your research.

EdgeBio公司的主要产品包括：

Accessories

Sequencing Clean-Up

PCR Purification

Sample Preparation

Competent Cells

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

PhosphoSolutions成立于2001年，由Drs. Michael D. Browning, John W. Haycock, and Andrew J. Czernik 等一同创立，已发展成为在神经科学领域的蛋白及抗体的领先供应商。

PhosphoSolutions was founded in 2001 by Drs. Michael D. Browning, John W. Haycock, and Andrew J. Czernik who all worked together in the laboratory of Dr. Paul Greengard, co-recipient of the 2000 Nobel Prize in Medicine for his work on the role of protein phosphorylation in signal transduction in the nervous system. This expertise has led us to focus primarily on proteins of interest in the neuroscience field.

PhosphoSolutions公司的主要产品包括：

Cardiovascular

Catecholamine Signaling

Cell Markers

Cytoskeletal and Nuclear Proteins

DNA Damage

Extracellular Matrix Proteins

GABA Receptors

Glutamate Receptors and Associated Signaling Proteins

Hormone Biosynthesis

Neurodegenerative Disease

Neurogenesis and Development

Neurotransmission

Oncoproteins

RNA Processing

Signal Transduction

Steroid Hormone Receptors

Synaptic Vesicle Proteins

Uncategorized

Visual System

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

艾美捷科技特约代理Avidity Biosciences公司产品。

Avidity Biosciences公司位于美国加州La Jolla，是一家专门从事抗体寡核苷酸结合物（AOC™）技术开发的生物技术公司，此项技术结合了单抗组织选择性和寡核苷酸疗法的精确性，克服了寡核苷酸给药屏障。

Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.

Antibody oligonucleotide conjugate (AOC™) technology

Avidity’s antibody oligonucleotide conjugate (AOC™) technology utilizes antibodies to target cells and tissues of interest and facilitate the uptake and internalization of oligonucleotide payloads. By combining the cellular and tissue selectivity of antibodies with the selectivity and efficiency of oligo-based approaches, Avidity has demonstrated modulation of disease-related RNAs in diverse cell types and tissues including muscle, heart, liver, tumors and immune cells.